Evolving Immunotherapy Approaches for Renal Cell Carcinoma

Metastatic renal cell carcinoma (mRCC) continues to be associated with high rates of morbidity and mortality. Renal cell carcinoma (RCC) is typically resistant to cytotoxic chemotherapy, and while targeted therapies have activity and prolong progression-free and overall survival, responses are usual...

Full description

Saved in:
Bibliographic Details
Published in:Current oncology reports 2016-09, Vol.18 (9), p.57-57, Article 57
Main Authors: Curtis, Susanna A., Cohen, Justine V., Kluger, Harriet M.
Format: Article
Language:English
Subjects:
Carcinoma, Renal Cell - immunology
Carcinoma, Renal Cell - pathology
Carcinoma, Renal Cell - therapy
Cell therapy
Cell- and Tissue-Based Therapy
Chemotherapy
Cytokines
Cytokines - immunology
Cytotoxicity
Genitourinary Cancers (DP Petrylak and JW Kim
Humans
Immune checkpoint
Immune system
Immunotherapy
Immunotherapy, Active
Kidney cancer
Medicine
Medicine & Public Health
Metastases
Morbidity
Oncology
Renal cell carcinoma
Section Editors
Topical Collection on Genitourinary Cancers
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Metastatic renal cell carcinoma (mRCC) continues to be associated with high rates of morbidity and mortality. Renal cell carcinoma (RCC) is typically resistant to cytotoxic chemotherapy, and while targeted therapies have activity and prolong progression-free and overall survival, responses are usually not durable. Modulating the immune system with cytokine therapy, vaccine therapy, cell therapy, and checkpoint inhibitors offers hope of prolonged survival. Standard and emerging immune therapy approaches and combinations of immune therapies and other modalities are reviewed.
ISSN:1523-3790
1534-6269
DOI:10.1007/s11912-016-0542-9